Extended Data Fig. 7: TNBC tumour growth and immune infiltration in murine models.
From: Parity and lactation induce T-cell-mediated breast cancer protection
a, Tumour growth (left) and endpoint tumour volume (right) of AT3-OVA cells in the 4th MFP of RAG2−/−γc−/− mice pre-inoculated with naive OT-I cells seven days prior to mating in d10-FW (n = 4) and age-matched virgin (n = 4) control mice. b, Numbers of indicated immune cell populations in RAG2−/−γc−/− mice pre-inoculated with effector OT-I cells seven days prior to mating in d28-inv (n = 10) and age-matched virgin (n = 10) control mice. c, Numbers of indicated immune cell subpopulations per gram of AT3-OVA tumour from virgin (n = 6) and d10-FW (n = 6) RAG2−/−γc−/− mice at four weeks post tumour cell injection. d, Tumour growth (left) and endpoint tumour burden (right) of AT3-OVA cells in the 4th MFP of RAG−/−1−/− mice. Mice were injected with 20 × 106 effector gBT-I cells or PBS control eight weeks prior to injection of AT3-OVA cells (n = 5 per group for tumour growth and 10 for endpoint weight). Data in graphs represent mean ± s.e.m. Results are representative of n = 2 independent experiments (a, d left) or two combined independent experiments (b-d right). Statistical significance determined by two-sided Mann-Whitney test. Exact p values are shown.
